

1 **Preoperative COVID-19 Vaccination is Associated with Decreased Perioperative Mortality**
2 **after Major Vascular Surgery**

3 Molly Ratner MD^{1*}, Karan Garg MD^{1*}, Heepeel Chang MD², Anjali Nigalaye MD³, Steven
4 Medvedosky BS¹, Glenn Jacobowitz MD¹, Jeffrey J Siracuse MD⁴, Virendra Patel MD⁵, Marc
5 Schermerhorn MD⁶, Charles DiMaggio PhD¹, Caron B Rockman MD¹

6
7 ¹Division of Vascular and Endovascular Surgery, Department of Surgery, New York University
8 Langone Medical Center, New York, NY.

9 ²Division of Vascular Surgery, Department of Surgery, Westchester Medical Center, Valhalla,
10 NY.

11 ³ Division of Hospitalist Medicine, Department of Medicine, Mount Sinai Beth Israel Hospital,
12 New York, NY.

13 ⁴Division of Vascular and Endovascular Surgery, Department of Surgery, Boston Medical
14 Center, Boston, Massachusetts

15 ⁵Division of Vascular and Endovascular Interventions, Department of Surgery, New York
16 Presbyterian- Columbia University Irving Medical Center, New York, NY

17 ⁶Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess
18 Medical Center, Boston, Massachusetts

19

20 *Drs Molly Ratner and Karan Garg contributed equally to this manuscript.

21

22

23

24 **Pre-publication Corresponding Author**

25 Molly Ratner, MD

26 Division of Vascular and Endovascular Surgery

27 Department of Surgery

28 New York University Langone Medical Center, NYU Grossman School of Medicine

29 550 First Avenue, New York, NY 10016, USA

30 Phone: 212-263-7311

31 Molly.ratner@nyulangone.org

32

33 **Word Count:** 4952

34

35

36

37

38

39

40

41

42

43

44

45

46

47 **Abstract**

48 **Background:** The objective of this study was to examine the effect of COVID-19 vaccination
49 on perioperative outcomes after major vascular surgery.

50

51 **Methods:** This is a multicenter retrospective study of patients who underwent major vascular
52 surgery between December 2021 through August 2023. The primary outcome was all-cause
53 mortality within 30 days of index operation or prior to hospital discharge. Multivariable models
54 were used to examine the association between vaccination status and the primary outcome.

55

56 **Results:**

57 Of the total 85,424 patients included, 19161 (22.4%) were unvaccinated. Unvaccinated patients
58 were younger compared to vaccinated patients (mean age 68.44 +/- 10.37 years vs 72.11 +/- 9.20
59 years, $p < .001$) and less likely to have comorbid conditions, including hypertension (87.2% vs
60 89.7%, $p < .001$), congestive heart failure (14.5% vs 15.9%, $p < .001$), chronic obstructive
61 pulmonary disease (35.7% vs 36.3, $p < .001$) and renal failure requiring hemodialysis (1.4% vs
62 1.7%, $p = .005$). After risk factor adjustment, vaccination was associated with decreased
63 mortality (OR 0.7, 95% CI 0.62 - 0.81, $p < .0001$). Stratification by procedure type demonstrated
64 that vaccinated patients had decreased odds of mortality after open AAA (OR 0.6, 95% CI 0.42-
65 0.97, $p = 0.03$), EVAR (OR 0.6, 95% CI 0.43-0.83, $p = 0.002$), CAS (OR 0.7, 95% CI 0.51-0.88, p
66 $= 0.004$) and infra-inguinal lower extremity interventions (OR 0.7, 95% CI 0.48-0.96, $p = 0.03$).

67

68 **Conclusions:**

69 COVID-19 vaccination is associated with reduced perioperative mortality in patients undergoing
70 vascular surgery. This association is most pronounced for patients undergoing aortic aneurysm
71 repair, carotid stenting and infrainguinal bypass.

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92 **Introduction**

93 Although primarily an infection of the respiratory tract, Coronavirus Disease 2019 (COVID-19)
94 generates a systemic inflammatory state leading to dysregulation of and injury to multiple organ
95 systems,¹⁻⁵ including the vasculature.^{6,7} In the perioperative period, it has been proposed that the
96 exaggerated immune response elicited by both surgical trauma and severe acute respiratory
97 syndrome coronavirus 2 (SARS-CoV-2) may be responsible for the increased risk of
98 perioperative mortality and morbidity in patients with active or recent infections.^{8,9} These
99 findings have prompted groups like the American Society of Anesthesiologists to recommend
100 delaying elective surgery in patients with COVID-19.¹⁰ However, as the pandemic enters a new
101 phase with widespread population immunity in the setting of vaccine development and/or prior
102 infection, risk stratification will need to reflect these changes.

103
104 COVID-19 vaccination has been associated with improved outcomes, including decreased
105 mortality, in patients undergoing various surgical procedures, such as cardiovascular,
106 gastrointestinal operations and orthopedic surgeries.¹¹⁻¹³ However, there is a paucity of literature
107 evaluating the effect of COVID-19 vaccination on perioperative outcomes after major vascular
108 surgery, specifically. In this retrospective cohort study, we utilized the Society for Vascular
109 Surgery Vascular Quality Initiative (SVS-VQI) database to examine national trends in
110 perioperative mortality after major vascular surgery in the post-vaccination stage of the
111 pandemic.

112

113 **Methods**

114 *Data Source*

115 This study utilized the SVS-VQI, a prospectively maintained set of 14 registries containing
116 standardized data collected from over 1000 institutions across the United States, Canada and
117 Singapore. The VQI stores demographic, perioperative and postoperative data on major vascular
118 procedures for the purpose of improving surgical outcomes. Approval was obtained from the
119 SVS VQI Patient Safety Organization prior to analysis. The study was exempt from Institutional
120 Board Review approval and individual patient consent was waived given its retrospective
121 nature.

122

123 *Study Population and Definitions*

124 The SVS-VQI was queried from the start of COVID vaccination data collection on December
125 16th, 2021, through its termination on August 31, 2023. Patients were included if they underwent
126 a “major” vascular surgery procedure (i.e. those performed mainly in a non-ambulatory setting),
127 including aortic aneurysm repair (open vs endovascular abdominal/thoracic), carotid artery
128 endarterectomy or stenting and open peripheral revascularization. Endovascular peripheral
129 vascular interventions (PVI) were excluded given the shift towards performing these procedures
130 in an outpatient or ambulatory care setting.¹⁴

131

132 The primary variable of interest was COVID vaccination status. Vaccinated patients included
133 those who had completed the full vaccine series by the time of surgery or had received at least
134 one vaccine with the intention of completing the series. Baseline characteristics, such as
135 demographic and medical history, were collected and included: age, sex, race, smoking status,
136 hypertension, hyperlipidemia, diabetes, coronary artery disease (CAD), congestive heart failure
137 (CHF), chronic obstructive pulmonary disease (COPD), cerebrovascular disease (CVD), renal

138 failure requiring hemodialysis (HD) and preoperative medication utilization. The urgency of the
139 case (i.e. elective vs urgent/emergent) was additionally considered a potential confounder.

140

141 *Outcomes:*

142 The primary outcome was perioperative all-cause mortality, defined as occurring either prior to
143 discharge from the hospital or within 30 days of index operation. The secondary endpoints were
144 surgery-specific perioperative mortality.

145

146 *Statistical Analysis*

147 All analyses were conducted in the R statistical software program. Comparisons of continuous
148 variables were based on t-tests and categorical variables were compared using Chi Square tests
149 as part of the `CratTableOne` function of the R `tableone` package. Unadjusted odds ratios (ORs)
150 for the association of COVID vaccination with perioperative mortality were calculated using the
151 `epitab` function of the R `epitools` package. Separate multivariable logistic regression models for
152 each type of procedure (open repair, EVAR, TEVAR, carotid endarterectomy, carotid artery
153 stenting, infrainguinal and suprainguinal revascularization) comparing the association of COVID
154 vaccination with perioperative mortality were adjusted for confounding by age, gender,
155 hypertension, diabetes, race, ethnicity, pre-operative history of smoking and whether the
156 procedure was elective or urgent. A single model with an additional control variable for the type
157 of procedure was run for the full combined data. An additional multilevel model which set the
158 intercept to vary by procedure type was created to establish a baseline risk for mortality risk for
159 each procedure cohort. Results of the multivariable and multilevel models are presented as ORs
160 with associated p-values and 95% confidence intervals (CIs).

161 **Results**

162 *Baseline Characteristics*

163 Of the total 85,424 patients identified, 19161 (22.4%) were unvaccinated at the time of index
164 operation. Unvaccinated patients were significantly younger compared to vaccinated patients
165 (mean age 68.44 +/- 10.37 years vs 72.11 +/- 9.20 years, $p < 0.001$). The majority of patients in
166 both cohorts were male (65.0% vs 65.6%, $p = 0.34$) and white, although black patients were
167 over-represented in the unvaccinated group (8.3% vs 7.6%, $p = 0.001$). Unvaccinated patients
168 were more likely to be current smokers (39.4% vs 25.5%, $p < 0.001$) compared to vaccinated
169 patients. Unvaccinated patients were less likely to have a history of hypertension (87.2% vs
170 89.7%, $p < 0.001$), CHF (14.5% vs 15.9%, $p < 0.001$), COPD (35.7% vs 36.3, $p < 0.001$) and HD
171 dependence (1.4% vs 1.7%, $p = 0.005$). Unvaccinated patients were additionally less likely to be
172 taking medications for cardiovascular risk reduction, including aspirin (75.2% vs 77.9%, p
173 < 0.001), statins (77.9% vs 84.7%, $p < 0.001$) and beta-blockers (44.9% vs 50.4%, $p < 0.001$).
174 Unvaccinated patients were more likely to have a positive pre- or postoperative positive COVID
175 test, although the overall incidence was low (1.9% vs 1.1%, $p < 0.001$). Unvaccinated patients
176 also less frequently underwent elective procedures (76.2% vs 83.5%, $p < 0.001$). See Table I for a
177 full list of baseline characteristics.

178

179 *Multivariable Model*

180 After adjusting for age, gender, race, ethnicity, smoking status, hypertension, diabetes, coronary
181 artery disease and dialysis, vaccinated status was associated with decreased mortality (OR 0.7,
182 95% CI 0.62 - 0.81, $p < 0.001$). A multilevel model with the same variables in the multivariable
183 logistic model with a random intercept by procedure type returned the same estimate for the

184 effect of the vaccine (OR 0.7, 95% CI 0.62 -0.81). After stratifying by procedure type,
185 vaccinated patients had decreased odds of mortality after open AAA (OR 0.6, 95% CI 0.42-0.97,
186 $p = 0.03$), EVAR (OR 0.6, 95% CI 0.43-0.83, $p = 0.002$), CAS (OR 0.7, 95% CI 0.51-0.88, $p =$
187 0.004) and infra-inguinal lower extremity interventions (OR 0.7, 95% CI 0.48-0.96, $p = 0.03$).
188 However, vaccinated status did not significantly reduce the odds of perioperative death in
189 patients who underwent TEVAR, CEA or supra-inguinal lower extremity intervention. See
190 Figure 1 for the Forest Plot.

191

192 *Procedure Type:*

193 *AORTIC SURGERY (TABLE II):*

194 Similar to the overall cohort population, unvaccinated patients undergoing OAR, EVAR and
195 TEVAR were significantly younger than their vaccinated counterparts. Unlike the general
196 cohort, baseline comorbidities were similar between vaccinated and unvaccinated patients with a
197 few notable exceptions. Vaccinated patients who underwent TEVAR were more likely to have
198 preoperative diabetes (19.5% vs 15.3%, $p = 0.002$) and CAD (21.4% vs 18.1%, $p = 0.02$)
199 compared to the unvaccinated cohort. For all patients undergoing aortic surgery, vaccinated
200 patients were more likely to be on aspirin and statins. In this cohort, unvaccinated patients were
201 significantly less likely than vaccinated patients to undergo surgery electively. Vaccinated
202 patients who underwent OAR and EVAR were less likely to have a positive covid diagnosis
203 (0.9% vs 4.1%, $p = 0.02$; 1.4% vs 3.1%, $p < 0.001$) and perioperative mortality was significantly
204 lower compared to unvaccinated patients (7.1% vs 10.7%, $p = 0.02$; 3.1% vs 1.4%, $p < 0.001$).
205 There was no significant difference in covid status or perioperative mortality between
206 unvaccinated and vaccinated patients who underwent TEVAR.

207

208 *Carotid Artery Revascularization (Table III)*

209 Similar to the overall patient cohort, vaccinated patients undergoing CAS and CEA were more
210 likely to have a variety of medical comorbidities including hypertension, diabetes, and CHF.
211 Notably, however, they were less likely than unvaccinated patients to have a history of CVD
212 (54% vs 59.6%, $p < 0.001$; 48.8% vs 55.2%, $p < 0.001$). Vaccinated patients who underwent
213 carotid revascularization were more likely to be on an aspirin, statin, ACE-inhibitor, or beta-
214 blocker. Vaccinated patients who underwent CAS were less likely to have a positive covid
215 diagnosis (1.0% vs 1.6%, $p < .001$) and peri-operative mortality was significantly reduced
216 compared to the unvaccinated cohort (0.7% vs 1.3%, $p < 0.001$). There was no significant
217 difference in covid status or perioperative mortality between unvaccinated and vaccinated
218 patients who underwent CEA.

219

220 *Peripheral Revascularization (Table IV)*

221 Unlike the overall study population or patients undergoing infra-inguinal bypass, white patients
222 were over-represented in the unvaccinated cohort who underwent supra-inguinal bypass (82.9%
223 vs 75.2%, $p < 0.001$). Vaccinated patients who underwent peripheral revascularization were more
224 likely to have a history of HTN, diabetes, and HD and to be on ACE-inhibitors or beta-blockers.
225 In patients undergoing supra-inguinal bypass, there was no significant difference in the
226 likelihood of undergoing an elective procedure between vaccinated and unvaccinated patients.
227 In patients with underwent either supra- or infrainguinal bypass, there was no significant
228 difference in the proportion of vaccinated and unvaccinated patients with a positive COVID
229 diagnosis and there was no significant difference in perioperative mortality.

230 **Discussion**

231 In this retrospective analysis of a large, multicenter database, vaccination against COVID was
232 significantly associated with reduced perioperative mortality after major vascular surgery.
233 Despite presenting with a high burden of comorbid conditions, including hypertension, diabetes
234 and coronary artery disease, vaccinated patients had reduced odds of perioperative mortality after
235 open AAA, EVAR, CAS, and infra-inguinal lower extremity open revascularization procedures.
236 Our results underscore the efficacy of the COVID vaccination in reducing perioperative all-cause
237 mortality, particularly in older, high-risk patients.

238
239 Recently published reports have examined the protective effect of COVID vaccination amongst a
240 different subset of surgical patients. In a retrospective, multicenter cohort review of patients
241 undergoing high risk surgery, Sharath et al found that the unadjusted and adjusted 90-day
242 mortality rates between vaccinated patients with and without a recent COVID-19 diagnosis were
243 comparable. Moreover, in a subgroup analysis of matched vaccinated and unvaccinated COVID
244 positive patients, vaccination reduced 90-day mortality by close to 50%.¹⁵ In a second,
245 retrospective study of cardiac surgery patients, a cohort with similar risk factors to those
246 undergoing vascular surgery, Blumenfeld et al examined the effect of perioperative COVID-19
247 infection on 30-day mortality before and after the development of the COVID vaccine. The
248 authors reported a significantly elevated risk of perioperative mortality in COVID-19 positive
249 patients prior to vaccine availability. However, after universal vaccination protocols were put in
250 place, the association between COVID-19 infection and increased perioperative mortality was no
251 longer apparent.¹⁶ Although further research is needed, it has been proposed that the reduced

252 mortality may be attributed to effectiveness of the vaccine in quelling the systemic inflammatory
253 state induced by virus which is further heightened in the context of surgery.¹⁵

254

255 The reduced all-cause mortality seen in our study population of largely COVID negative patients
256 cannot be fully explained by the effectiveness of the vaccine in preventing COVID-19-related
257 deaths. A similar reduction in all-cause mortality was observed in a population-based study out
258 of Australia, in which the authors proposed several possible explanations for this finding,
259 including indirect reduction in outcomes associated with COVID-19 infection, such as
260 cardiovascular and pulmonary complications.¹⁷ Given that vascular surgery patients are amongst
261 the highest risk patients for postoperative cardiac complications,¹⁸ this hypothesis seems
262 reasonable. An additional consideration brought forth by the authors was the effect of
263 confounding, particularly in the form of behavioral differences such as the healthy vaccinee
264 effect.¹⁷ However, it is worth noting that vaccinated patients within our study tended to present
265 with more serious comorbid conditions which we believe reduces the likelihood that vaccination
266 status is a simply a marker for access to and trust in the health care system.

267

268 The higher proportion of older and sicker patients who were vaccinated in our study is consistent
269 with epidemiologic data within the United States. In the 2021, United States Census Bureau's
270 Household Pulse Survey of around 61,000 people, unvaccinated people were generally younger
271 with 75% of the unvaccinated population under the age of 50.¹⁹ This pattern of vaccination can
272 be at least partially attributed to the way the COVID vaccine was rolled out in most states with
273 priority given to older adults and those living in group living facilities. However, beyond
274 logistics, it is conceivable to believe that patients who are aware of serious comorbid conditions

275 may be more likely to vaccinate for specifically that reason, given the widespread knowledge
276 that people with these risk factors generally had worse outcomes with COVID infections. In fact,
277 studies have described the relationship between increasing age or pre-existing medical conditions
278 and the intention to vaccinate.²⁰⁻²² The US Census Survey additionally reported a higher
279 representation of non-Hispanic Black people within the unvaccinated cohort compared to the
280 vaccinated cohort (13% vs 11%),¹⁹ a finding mirrored within our own study population. The
281 significance of this disparity cannot be understated, particularly given the disproportionate
282 impact of both COVID 19 and atherosclerotic cardiovascular disease on black individuals.²³ A
283 more comprehensive understanding of what drives vaccine hesitancy amongst vascular surgery
284 patients should be undertaken to better address this issue.

285
286 During the height of the pandemic, major society guidelines suggested deferring elective
287 procedures for several weeks after COVID-19 infection.¹⁰ However, in the endemic phase of
288 COVID-19, as more patients have been exposed to the virus through infection and immunization,
289 guidelines around surgical timing are in flux. The results of our study, in conjunction with
290 others,^{15,24} suggests a protective effect of vaccination prior to surgery, particularly in patients
291 whose risk factors predispose them to needing surgical intervention in urgent or emergent
292 settings, such as those with vascular disease. However, further studies are needed to discern
293 optimal timing between vaccination and operative intervention to provide greatest protection.

294
295 There are several limitations to this study, including its retrospective observational nature. While
296 the use of the VQI-SVS database allowed us to capture a broader population, however, the
297 registry lacks granular detail. For instance, the extent of vascular disease with regards to anatomy

298 and morphology cannot be fully categorized. Furthermore, while data input is standardized, the
299 accuracy and completeness of the information is center specific. Certain variables, including the
300 length of time between vaccination and surgery, choice of vaccination, and implementation of
301 booster shots were not consistently input into the database, limiting the extent of the analysis we
302 were able to perform. Furthermore, the VQI does not generate data on the specific cause of
303 death, so analysis was limited to all-cause mortality. Successful recovery from COVID infection
304 confers a degree of immunity and it is unclear whether prior infection provides a synergetic,
305 reductive, or independent effect on vaccination protection against perioperative mortality.
306 Further longitudinal studies will be needed to elucidate these relationships.

307

308 CONCLUSION:

309 In our analysis of the Vascular Quality Initiative (VQI) database of all patients undergoing major
310 vascular interventions, we found an association between vaccination status and improved
311 perioperative survival. This association was most pronounced for patients undergoing AAA
312 repair, carotid stenting and infrainguinal bypass. As the pandemic enters the endemic stage,
313 future studies must focus on not only the prevention of viral infection in high-risk surgical
314 patients, but also on downstream benefits that vaccines may impart on society.

315

316 Acknowledgements: None

317 Funding: None

318 Disclosures: None

319

320

321 **REFERENCES**

- 322 1. Inciardi RM, Solomon SD, Ridker PM, Metra M. Coronavirus 2019 Disease (COVID-19),
323 Systemic Inflammation, and Cardiovascular Disease. *JAHA*. 2020;9(16):e017756.
324 doi:10.1161/JAHA.120.017756
- 325 2. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19.
326 *Am J Emerg Med*. 2020;38(7):1504-1507. doi:10.1016/j.ajem.2020.04.048
- 327 3. Janardhan V, Janardhan V, Kalousek V. COVID-19 as a Blood Clotting Disorder
328 Masquerading as a Respiratory Illness: A Cerebrovascular Perspective and Therapeutic
329 Implications for Stroke Thrombectomy. *J Neuroimaging*. 2020;30(5):555-561.
330 doi:10.1111/jon.12770
- 331 4. Chen YT, Shao SC, Hsu CK, Wu IW, Hung MJ, Chen YC. Incidence of acute kidney injury
332 in COVID-19 infection: a systematic review and meta-analysis. *Crit Care*. 2020;24(1):346.
333 doi:10.1186/s13054-020-03009-y
- 334 5. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver
335 involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet*
336 *Gastroenterol Hepatol*. 2020;5(7):667-678. doi:10.1016/S2468-1253(20)30126-6
- 337 6. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients
338 with COVID-19. *Lancet Haematol*. 2020;7(6):e438-e440. doi:10.1016/S2352-
339 3026(20)30145-9

- 340 7. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in
341 hospitalized patients with COVID-19. *J Thromb Haemost.* 2020;18(8):1995-2002.
342 doi:10.1111/jth.14888
- 343 8. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing
344 surgery with perioperative SARS-CoV-2 infection: an international cohort study. *Lancet.*
345 2020;396(10243):27-38. doi:10.1016/S0140-6736(20)31182-X
- 346 9. Doglietto F, Vezzoli M, Gheza F, et al. Factors Associated With Surgical Mortality and
347 Complications Among Patients With and Without Coronavirus Disease 2019 (COVID-19) in
348 Italy. *JAMA Surg.* 2020;155(8):691-702. doi:10.1001/jamasurg.2020.2713
- 349 10. Anesthesia Patient Safety Foundation. American Society of Anesthesiologists and
350 Anesthesia Patient Safety Foundation joint statement on elective surgery and anesthesia for
351 patients after COVID-19 infection. Accessed January 20, 2024. [https://www.apsf.org/news-](https://www.apsf.org/news-updates/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-for-patients-after-covid-19-infection/)
352 [updates/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-for-patients-after-](https://www.apsf.org/news-updates/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-for-patients-after-covid-19-infection/)
353 [covid-19-infection/](https://www.apsf.org/news-updates/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-for-patients-after-covid-19-infection/)
- 354 11. Jagadeesh N, Gnany J, Kapadi S, Koshy N, Shaw D. COVID-19 Vaccination: Does It Alter
355 Postoperative Mortality and Morbidity in Hip Fractures? *Cureus.* 2022;14(12):e32688.
356 doi:10.7759/cureus.32688
- 357 12. Prasad NK, Lake R, Englum BR, et al. COVID-19 Vaccination Associated With Reduced
358 Postoperative SARS-CoV-2 Infection and Morbidity. *Annals of Surgery.* 2022;275(1):31-36.
359 doi:10.1097/SLA.0000000000005176

- 360 13. Prasad NK, Englum BR, Mayorga-Carlin M, et al. Partial COVID-19 vaccination associated
361 with reduction in postoperative mortality and SARS-CoV-2 infection. *Am J Surg*.
362 2022;224(4):1097-1102. doi:10.1016/j.amjsurg.2022.03.038
- 363 14. Mesbah Oskui P, Kloner RA, Burstein S, et al. The safety and efficacy of peripheral vascular
364 procedures performed in the outpatient setting. *J Invasive Cardiol*. 2015;27(5):243-249.
- 365 15. Sharath SE, Koungias P, Daviú-Molinari T, Faridmoayer E, Berger DH. Association Between
366 Coronavirus Disease 2019 Vaccination and Mortality After Major Operations. *Annals of*
367 *Surgery*. 2024;279(1):58-64. doi:10.1097/SLA.0000000000006051
- 368 16. Blumenfeld O, Rosenberg A, Reuven M, Caspi I, Sharoni E, Leviner DB. The effect of
369 COVID-19 vaccination on 30-day mortality after cardiac surgery – Insights from the Israel
370 national registries. *Infection Prevention in Practice*. 2024;6(1):100334.
371 doi:10.1016/j.infpip.2023.100334
- 372 17. Liu B, Stepien S, Dobbins T, et al. Effectiveness of COVID-19 vaccination against COVID-
373 19 specific and all-cause mortality in older Australians: a population based study. *The Lancet*
374 *Regional Health - Western Pacific*. 2023;40:100928. doi:10.1016/j.lanwpc.2023.100928
- 375 18. Beaulieu RJ, Sutzko DC, Albright J, Jeruzal E, Osborne NH, Henke PK. Association of High
376 Mortality With Postoperative Myocardial Infarction After Major Vascular Surgery Despite
377 Use of Evidence-Based Therapies. *JAMA Surg*. 2020;155(2):131.
378 doi:10.1001/jamasurg.2019.4908

- 379 19. US Bureau of Census. Household Pulse Survey Data. Published online 2021. Accessed
380 January 1, 2024. [https://www.census.gov/programs-surveys/household-pulse-](https://www.census.gov/programs-surveys/household-pulse-survey/data.html)
381 [survey/data.html](https://www.census.gov/programs-surveys/household-pulse-survey/data.html)
- 382 20. Daly M, Robinson E. Willingness to Vaccinate Against COVID-19 in the U.S.:
383 Representative Longitudinal Evidence From April to October 2020. *American Journal of*
384 *Preventive Medicine*. 2021;60(6):766-773. doi:10.1016/j.amepre.2021.01.008
- 385 21. Ruiz JB, Bell RA. Predictors of intention to vaccinate against COVID-19: Results of a
386 nationwide survey. *Vaccine*. 2021;39(7):1080-1086. doi:10.1016/j.vaccine.2021.01.010
- 387 22. Trent M, Seale H, Chughtai AA, Salmon D, MacIntyre CR. Trust in government, intention to
388 vaccinate and COVID-19 vaccine hesitancy: A comparative survey of five large cities in the
389 United States, United Kingdom, and Australia. *Vaccine*. 2022;40(17):2498-2505.
390 doi:10.1016/j.vaccine.2021.06.048
- 391 23. Carnethon MR, Pu J, Howard G, et al. Cardiovascular Health in African Americans: A
392 Scientific Statement From the American Heart Association. *Circulation*. 2017;136(21).
393 doi:10.1161/CIR.0000000000000534
- 394 24. Le ST, Kipnis P, Cohn B, Liu VX. COVID-19 Vaccination and the Timing of Surgery
395 Following COVID-19 Infection. *Annals of Surgery*. 2022;276(5):e265-e272.
396 doi:10.1097/SLA.00000000000005597
- 397
398
399

Table I: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing major vascular surgery

	Unvaccinated (n = 19161)	Vaccinated (n = 66263)	P Value
Age (mean +/- SD)	68.44 +/- 10.37	72.11 +/- 9.20	<0.001
Male	12461 (65.0%)	43479 (65.6%)	0.14
Race			
White	16191 (84.5%)	56359 (85.1%)	0.06
Black	1584 (8.3%)	5009 (7.6%)	.001
Current Smoker	7245 (37.8%)	16896 (25.5%)	<0.001
Former Smoker	7260 (37.9%)	33248 (50.2%)	<.001
Hypertension	16700 (87.2%)	59442 (89.7%)	<0.001
Diabetes	6957 (36.3%)	24225 (36.5%)	0.53
CAD	6422 (33.5%)	22601 (34.1%)	0.13
CABG	2944 (15.4%)	11438 (17.3%)	<0.001
PCI	4217 (22.0%)	15381 (23.2%)	0.001

CHF	2771 (14.5%)	10523 (15.9%)	<0.001
COPD	5423 (35.7%)	17633 (36.3%)	<0.001
Hemodialysis	270 (1.4%)	1129 (1.7%)	0.005
Preoperative Medications			
Aspirin	14413 (75.2%)	51610 (77.9%)	<0.001
Statin	14925 (77.9%)	56021 (84.7%)	<0.001
ACE inhibitor	9546 (49.8%)	35075 (53.0%)	<0.001
P2Y ₁₂ -Inhibitor	9470 (49.4%)	32123 (48.5%)	0.02
Anticoagulation	2511 (13.1%)	9698 (14.6%)	<0.001
Beta Blocker	8606 (44.9%)	33354 (50.4%)	<0.001
Elective Status	14593 (76.2%)	55252 (83.5%)	<0.001
Positive COVID Status	358 (1.9%)	734 (1.1%)	<0.001
Perioperative Mortality	360 (1.8%)	761 (1.1%)	<0.001

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.

Table II: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing aortic surgery

Variable	OPEN			EVAR			TEVAR		
	Unvaccinated (n= 394)	Vaccinated (n = 1559)	P value	Unvaccinated (n= 2149)	Vaccinated (n= 8970)	P value	Unvaccinated (n = 1075)	Vaccinated (n = 3404)	P value
Age (mean +/- SD)	67.29 +/- 9.22	69.90 +/- 8.38	<0.001	71.76 +/- 9.08	74.28 +/- 8.38	<0.001	65.64 +/- 13.30	70.91 +/- 11.11	<0.001
Male	283 (71.8%)	1179 (75.6%)	0.14	1709 (79.5%)	7214 (80.5)	0.60	711 (66.1%)	2250 (66.1)	0.73
Race									
White	331 (84.0%)	1204 (77.3%)	0.004	151 (7.0%)	563 (6.3%)	.20	674 (62.7%)	2360 (69.4%)	<0.001
Black	22 (5.6%)	78 (5.0%)	0.64	1801 (83.9%)	7539 (84.1%)	.85	242 (22.5%)	535 (15.7%)	<0.001
Current Smoker	147 (37.4%)	757 (48.7%)	<0.001	939 (43.8%)	2673 (29.8%)	<0.001	432 (40.3%)	978 (28.8%)	<0.001
Former Smoker	204 (51.9%)	630 (40.5%)	<0.001	909 (42.4%)	4985 (55.6%)	<0.001	380 (35.4%)	1664 (48.9%)	<0.001

Hypertension	318 (80.7%)	1305 (83.8%)	0.16	1794 (83.5%)	7698 (85.9%)	0.005	979 (91.2%)	3099 (91.1%)	0.98
Diabetes	64 (16.2%)	271 (17.4%)	0.64	442 (20.6%)	1924 (21.5%)	0.38	164 (15.3%)	665 (19.5%)	0.002
CAD	82 (20.8%)	348 (22.4%)	0.54	574 (26.7%)	2509 (28.0%)	0.24	195 (18.1%)	727 (21.4%)	0.02
Prior CABG	43 (10.9%)	174 (11.2%)	0.95	297 (13.8%)	1328 (14.8%)	0.26	93 (8.7%)	400 (11.8%)	0.006
Prior PCI	67 (17.0%)	290 (18.6%)	0.50	478 (22.3%)	2048 (22.9%)	0.59	147 (13.7%)	576 (16.9%)	0.01
CHF	33 (8.4%)	156 (10.0%)	0.37	304 (14.2%)	1319 (14.7%)	0.53	190 (17.7%)	574 (16.9%)	0.57
COPD	128 (32.5%)	524 (33.7%)	0.71	747 (34.8%)	3096 (34.5%)	0.86	352 (32.7%)	1157 (34.0%)	0.47
Hemodialysis	2 (0.5%)	8 (0.5%)	1.00	27 (1.3%)	96 (1.1%)	0.53	30 (2.8%)	91 (2.7%)	0.92
Preop Medications									
Aspirin	207 (52.7%)	923 (59.4%)	0.02	1207 (56.2%)	5255 (58.7%)	0.04	575 (53.5%)	2015 (59.3%)	0.001
Statins	242 (61.6%)	1193 (76.7%)	<0.001	1415 (65.9%)	6822 (76.2%)	<0.001	618 (57.5%)	2416	<0.001

								(71.1%)	
ACE-inhibitor	152 (38.7%)	738 (47.4%)	0.002	975 (45.4%)	4310 (48.1%)	0.02	488 (45.4%)	1561 (45.9%)	0.82
P2Y ₁₂ inhibitors	32 (8.1%)	126 (8.1%)	1.00	333 (15.5%)	1195 (13.3%)	0.01	144 (13.4%)	406 (11.9%)	0.22
Anticoagulation	37 (9.4%)	206 (13.2%)	0.05	337 (15.7%)	1572 (17.5%)	0.04	163 (15.2%)	630 (18.5%)	0.01
Beta-blocker	168 (42.9%)	760 (48.8%)	0.04	1004 (46.8%)	4555 (50.8%)	0.001	730 (67.9%)	2248 (66.0%)	0.27
Elective	281 (71.3%)	1210 (77.6%)	0.01	1631 (76.2%)	7787 (86.9%)	<0.001	706 (65.7%)	2694 (79.2%)	<0.001
Positive COVID Status	16 (4.1%)	14 (0.9%)	<0.001	41 (1.9%)	103 (1.2%)	0.005	26 (2.4%)	58 (1.7%)	0.13
Mortality	42 (10.7%)	111 (7.1%)	0.02	67 (3.1%)	127 (1.4%)	<0.001	57 (5.3%)	141 (4.2%)	0.11

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.

Table III: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing carotid artery revascularization

Variable	CAS			CEA		
	Unvaccinated (n = 6933)	Vaccinated. (n = 22308)	P value	Unvaccinated (n = 5790)	Vaccinated (n = 20506)	P Value
Age (mean +/- SD)	69.83 +/- 10.18	73.16 +/- 8.98	<0.001	69.07 +/- 9.53	72.02 +/- 8.61	<0.001
Male	4306 (62.1%)	14008 (62.8%)	0.30	3509 (60.6%)	12288 (59.9%)	0.58
Race						
White	6075 (87.7%)	19881 (89.1%)	0.001	5157 (89.1%)	18331 (89.5%)	0.42
Black	442 (6.4%)	1270 (5.7%)	0.04	280 (4.8%)	1065 (5.2%)	0.27
Current Smoker	2245 (32.5%)	4481 (20.1%)	<0.001	1915 (33.1%)	4515 (22.0%)	<0.001
Former Smoker	2660 (38.5%)	11152 (50.0%)	<0.001	2265 (39.1%)	10194 (49.7%)	<0.001
Hypertension	6089 (87.9%)	20235 (90.7%)	<0.001	5161 (89.1%)	18604 (90.8%)	<0.001
Diabetes	2585 (37.3%)	8826 (39.6%)	0.001	2110 (36.4%)	7911 (38.6%)	<0.001
CAD	3141 (45.3%)	10805 (48.5%)	<0.001	1618 (27.9%)	5527 (27.0%)	0.15

Prior CABG	1126 (16.3%)	4233 (19.0%)	<0.001	958 (16.6%)	3604 (17.6%)	0.07
Prior PCI	1659 (24.0%)	5826 (26.2%)	<0.001	1239 (21.4%)	4506 (22.0%)	0.35
CHF	1038 (15.0%)	3759 (16.9%)	<0.001	710 (12.3%)	2781 (13.6%)	0.01
COPD	1636 (23.6%)	5282 (23.7%)	0.89	1343 (23.2%)	4696 (22.9%)	0.66
CVD	4127 (59.6%)	12031 (54.0%)	<0.001	3196 (55.2%)	9997 (48.8%)	<0.001
Hemodialysis	89 (1.3%)	286 (1.3%)	1.00	48 (0.8%)	217 (1.1%)	0.14
Preoperative Medications						
Aspirin	5745 (82.9%)	19499 (87.5%)	<0.001	4707 (81.4%)	17086(83.4%)	<0.001
Statin	5721 (82.6%)	19679 (88.3%)	<0.001	4757 (82.2%)	18066(88.2%)	<0.001
ACE-inhibitor	3483 (50.3%)	12064 (54.1%)	<0.001	3057 (52.8%)	11287 (55.1%)	0.002
P2Y ₁₂ -inhibitor	5522 (79.7%)	19057 (85.5%)	<0.001	2459 (42.5%)	8320 (40.6%)	0.01
Anticoagulation	409 (6.4%)	1463 (7.3%)	0.02	784 (13.5%)	3091 (15.1%)	0.004
Beta-blocker	3085 (44.5%)	11207 (50.3%)	<0.001	2448 (42.3%)	9815 (47.9%)	<0.001
Elective	5201 (75.1%)	18367 (82.5%)	<0.001	4696 (81.1%)	17845 (87.0%)	<0.001
Positive COVID	114 (1.6%)	216 (1.0%)	<.001	110 (1.2%)	208 (1.0%)	.20

Status						
Mortality	88 (1.3%)	157 (0.7%)	<.001	22 (0.4%)	62 (0.3%)	.36

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; CVD, cerebrovascular disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.

Table IV: Baseline comorbidities and characteristics of unvaccinated and vaccinated patients undergoing revascularization for peripheral artery disease.

	SUPRAINGUINAL			INFRAINGUINAL		
	Unvaccinated (N = 620)	Vaccinated (N = 1635)	P Value	Unvaccinated (n = 2200)	Vaccinated (n = 7881)	P Value
Age (mean +/- SD)	62.15 +/- 9.866	66.81 +/- 9.682	<0.001	64.90 +/-10.412	68.87 +/- 9.928	<0.001
Male	383 (61.8%)	957 (58.5%)	0.32	1560 (70.9%)	5584 (70.9%)	0.87
Race						0.10
White	513 (82.9%)	1228 (75.2%)	<0.001	1640 (74.5%)	5816 (73.8%)	0.51
Black	65 (10.5%)	190 (11.6%)	0.45	382 (17.4%)	1308 (16.6%)	0.40
Current Smoker	407 (65.6%)	816 (49.9%)	<0.001	1160 (52.8%)	2804 (35.6%)	<0.001
Former Smoker	192 (31.0%)	745 (45.6%)	<0.001	710 (32.3%)	3751 (47.6%)	<0.001
Hypertension	502 (81.1%)	1393 (85.3%)	0.02	1857 (84.5%)	7108 (90.2%)	<0.001
Diabetes	164 (26.5%)	526 (32.2%)	0.01	1068 (48.6%)	4102 (52.1%)	0.01
CAD	158 (25.5%)	402 (24.7%)	0.68	654 (31.3%)	2283 (30.5%)	0.49
Prior CABG	56 (9.0%)	209 (12.8%)	0.01	371 (16.9%)	1490 (18.9%)	0.03

Prior PCI	109 (17.6%)	285 (17.4%)	0.94	518 (23.6%)	1850 (23.5%)	0.94
CHF	67 (10.8%)	219 (13.4%)	0.10	429 (19.5%)	1715 (21.8%)	0.02
COPD	208 (33.5%)	644 (39.4%)	0.01	619 (28.2%)	2234 (28.4%)	0.87
Hemodialysis	5 (0.8%)	38 (2.3%)	0.02	69 (3.1%)	393 (5.0%)	<0.001
Preoperative Medications						
Aspirin	445 (71.9%)	1177 (72.0%)	0.96	1527 (69.4%)	5655 (71.8%)	0.03
Statin	485 (78.4%)	1319 (80.7%)	0.22	1687 (76.8%)	6526 (82.9%)	<0.001
ACE-inhibitor	279 (45.1%)	831 (50.8%)	0.02	1112 (50.6%)	4284 (54.4%)	0.002
P2Y ₁₂ -inhibitor	154 (24.9%)	354 (21.7%)	0.10	826 (37.6%)	2665 (33.8%)	0.001
AC	140 (22.6%)	343 (22.0%)	0.40	641 (29.1%)	2393 (30.4%)	0.27
Beta-blocker	222 (35.9%)	687 (42.0%)	0.01	949 (43.2%)	4082 (51.8%)	<0.001
Elective	461 (74.5%)	1259 (77.1%)	0.20	1617 (73.6%)	6090 (77.3%)	<0.001
Positive COVID Status	10 (1.6%)	21 (1.3%)	0.55	41 (1.9%)	114 (1.4%)	0.16
Mortality	25 (4.0%)	59 (3.6%)	0.64	34 (1.5%)	104 (1.3%)	0.42

CAD, coronary artery disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CHF, congestive heart failure; CVD, cerebrovascular disease; ACE-inhibitor, angiotensin converting enzyme inhibitor

Bold faced p values indicate significance.

Figure 1: Forest Plot Evaluating COVID Vaccination Status and Mortality

